Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Wong Mito Lab, |
RCV000500701 | SCV000598466 | uncertain significance | Mitochondrial DNA depletion syndrome 13 | 2017-08-10 | criteria provided, single submitter | reference population | The NM_012160.4:c.1464A>G (NP_036292.2:p.Arg488=) [GRCH38: NC_000006.12:g.98875653T>C] variant in FBXL4 gene is interpretated to be a Uncertain Significance - Conflicting Evidence based on ACMG guidelines (PMID: 25741868). This variant meets one or more of the following evidence codes reported in the ACMG-guideline. PM2:This variant is absent in key population databases. BP4:Computational evidence/predictors indicate no impact on the FBXL4 structure, function, or protein-protein interaction. BP7:The variant is silent with non predicted splice impact. Based on this evidence code ClinGen Pathogenicity Calculator (PMID:28081714) suggested that the variant is Uncertain Significance - Conflicting Evidence. |
Ce |
RCV003311830 | SCV004011692 | likely benign | not provided | 2023-05-01 | criteria provided, single submitter | clinical testing | FBXL4: BP4, BP7 |
Breakthrough Genomics, |
RCV003311830 | SCV005189163 | uncertain significance | not provided | criteria provided, single submitter | not provided | ||
Prevention |
RCV003925499 | SCV004744013 | likely benign | FBXL4-related disorder | 2019-09-26 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |